Por favor, use este identificador para citar o enlazar este Item:http://hdl.handle.net/20.500.12105/20422
Título
Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study
Autor(es)
Almeida, Antonio M | Prebet, Thomas | Itzykson, Raphael | Ramos, Fernando | Al-Ali, Haifa | Shammo, Jamile | Pinto, Ricardo | Maurillo, Luca | Wetzel, Jaime | Musto, Pellegrino | Van De Loosdrecht, Arjan A | Costa, Maria Joao | Esteves, Susana | Burgstaller, Sonja | Stauder, Reinhard | Autzinger, Eva M | Lang, Alois | Krippl, Peter | Geissler, Dietmar | Falantes, Jose F | Pedro, Carmen | Bargay Lleonart, Joan | Deben, Guillermo | Garrido, Ana | Bonanad, Santiago | Diez-Campelo, Maria | Thepot, Sylvain | Ades, Lionel | Sperr, Wolfgang R | Valent, Peter | Fenaux, Pierre | Sekeres, Mikkael A | Greil, Richard | Pleyer, Lisa
Fecha de publicación
2017-04
Cita
Almeida AM, Prebet T, Itzykson R, Ramos F, Al-Ali H, Shammo J, et al. Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. Int J Mol Sci. 2017 Apr;18(4):837.
Idioma
Inglés
Tipo de documento
research article
Resumen
Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3-9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is limited data of their efficacy in AEL. We collected data from 210 AEL patients treated at 28 international sites. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method and the log-rank test was used for subgroup comparisons. Survival between treatment groups was compared using the Cox proportional hazards regression model. Eighty-eight patients were treated with HMAs, 44 front line, and 122 with intensive chemotherapy (ICT). ICT led to a higher overall response rate (complete or partial) compared to first-line HMA (72% vs. 46.2%, respectively; p <= 0.001), but similar progression-free survival (8.0 vs. 9.4 months; p = 0.342). Overall survival was similar for ICT vs. HMAs (10.5 vs. 13.7 months; p = 0.564), but patients with high-risk cytogenetics treated with HMA first-line lived longer (7.5 for ICT vs. 13.3 months; p = 0.039). Our results support the therapeutic value of HMA in AEL.
Palabras clave
MESH
Leukemia, Erythroblastic, Acute | Aged, 80 and over | Aged | Bone Marrow | Adult | Azacitidine | Humans | Cytogenetic Analysis | Antineoplastic Combined Chemotherapy Protocols | Middle Aged | Male | Biomarkers | Decitabine | Female | Proportional Hazards Models | Treatment Outcome | Survival Analysis | Retrospective Studies
DECS
Modelos de Riesgos Proporcionales | Resultado del Tratamiento | Biomarcadores | Análisis Citogenético | Análisis de Supervivencia | Femenino | Decitabina | Masculino | Azacitidina | Humanos | Persona de Mediana Edad | Protocolos de Quimioterapia Combinada Antineoplásica | Anciano | Anciano de 80 o más Años | Médula ósea | Estudios Retrospectivos | Adulto | Leucemia Eritroblástica Aguda
Versión en línea
DOI
Aparece en las colecciones
Acceso a texto completo